Literature DB >> 23268326

Changes in selenoprotein P in substantia nigra and putamen in Parkinson's disease.

Frederick P Bellinger1, Arjun V Raman, Rachel H Rueli, Miyoko T Bellinger, Andrea S Dewing, Lucia A Seale, Marilou A Andres, Jane H Uyehara-Lock, Lon R White, G Webster Ross, Marla J Berry.   

Abstract

Oxidative stress and oxidized dopamine contribute to the degeneration of the nigrostriatal pathway in Parkinson's disease (PD). Selenoproteins are a family of proteins containing the element selenium in the form of the amino acid selenocysteine, and many of these proteins have antioxidant functions. We recently reported changes in expression of the selenoprotein, phospholipid hydroperoxide glutathione peroxidase GPX4 and its co-localization with neuromelanin in PD brain. To further understand the changes in GPX4 in PD, we examine here the expression of the selenium transport protein selenoprotein P (Sepp1) in postmortem Parkinson's brain tissue. Sepp1 in midbrain was expressed in neurons of the substantia nigra (SN), and expression was concentrated within the centers of Lewy bodies, the pathological hallmark of PD. As with GPX4, Sepp1 expression was significantly reduced in SN from PD subjects compared with controls, but increased relative to cell density. In putamen, Sepp1 was found in cell bodies and in dopaminergic axons and terminals, although levels of Sepp1 were not altered in PD subjects compared to controls. Expression levels of Sepp1 and GPX4 correlated strongly in the putamen of control subjects but not in the putamen of PD subjects. These findings indicate a role for Sepp1 in the nigrostriatal pathway, and suggest that local release of Sepp1 in striatum may be important for signaling and/or synthesis of other selenoproteins such as GPX4.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23268326      PMCID: PMC3527083          DOI: 10.3233/JPD-2012-11052

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  34 in total

1.  Involvement of selenoprotein P in protection of human astrocytes from oxidative damage.

Authors:  Holger Steinbrenner; Lirija Alili; Esra Bilgic; Helmut Sies; Peter Brenneisen
Journal:  Free Radic Biol Med       Date:  2006-01-13       Impact factor: 7.376

2.  SBP2 binding affinity is a major determinant in differential selenoprotein mRNA translation and sensitivity to nonsense-mediated decay.

Authors:  Jeffrey E Squires; Ilko Stoytchev; Erin P Forry; Marla J Berry
Journal:  Mol Cell Biol       Date:  2007-09-10       Impact factor: 4.272

3.  Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning.

Authors:  Edwin J Weeber; Uwe Beffert; Chris Jones; Jill M Christian; Eckart Forster; J David Sweatt; Joachim Herz
Journal:  J Biol Chem       Date:  2002-08-07       Impact factor: 5.157

4.  Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2.

Authors:  Uwe Beffert; Edwin J Weeber; Andre Durudas; Shenfeng Qiu; Irene Masiulis; J David Sweatt; Wei-Ping Li; Giselind Adelmann; Michael Frotscher; Robert E Hammer; Joachim Herz
Journal:  Neuron       Date:  2005-08-18       Impact factor: 17.173

5.  Association of selenoprotein p with Alzheimer's pathology in human cortex.

Authors:  Frederick P Bellinger; Qing-Ping He; Miyoko T Bellinger; Yanling Lin; Arjun V Raman; Lon R White; Marla J Berry
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 6.  Description of Parkinson's disease as a clinical syndrome.

Authors:  Stanley Fahn
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

7.  Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes.

Authors:  J K Wang
Journal:  J Neurochem       Date:  1991-09       Impact factor: 5.372

Review 8.  The Sep15 protein family: roles in disulfide bond formation and quality control in the endoplasmic reticulum.

Authors:  Vyacheslav M Labunskyy; Dolph L Hatfield; Vadim N Gladyshev
Journal:  IUBMB Life       Date:  2007-01       Impact factor: 3.885

9.  Post-translational processing of selenoprotein P: implications of glycosylation for its utilisation by target cells.

Authors:  Holger Steinbrenner; Lirija Alili; Dominik Stuhlmann; Helmut Sies; Peter Brenneisen
Journal:  Biol Chem       Date:  2007-10       Impact factor: 3.915

10.  Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease.

Authors:  Jeff Blackinton; Ravindran Kumaran; Marcel P van der Brug; Rili Ahmad; Lars Olson; Dagmar Galter; Andrew Lees; Rina Bandopadhyay; Mark R Cookson
Journal:  Neurosci Lett       Date:  2009-01-06       Impact factor: 3.046

View more
  17 in total

Review 1.  Regulated necrosis: disease relevance and therapeutic opportunities.

Authors:  Marcus Conrad; José Pedro Friedmann Angeli; Peter Vandenabeele; Brent R Stockwell
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

2.  Cerebrospinal fluid of newly diagnosed amyotrophic lateral sclerosis patients exhibits abnormal levels of selenium species including elevated selenite.

Authors:  Marco Vinceti; Nikolay Solovyev; Jessica Mandrioli; Catherine M Crespi; Francesca Bonvicini; Elisa Arcolin; Eleni Georgoulopoulou; Bernhard Michalke
Journal:  Neurotoxicology       Date:  2013-05-31       Impact factor: 4.294

Review 3.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

Review 4.  Selenoproteins in nervous system development and function.

Authors:  Matthew W Pitts; China N Byrns; Ashley N Ogawa-Wong; Penny Kremer; Marla J Berry
Journal:  Biol Trace Elem Res       Date:  2014-07-01       Impact factor: 3.738

Review 5.  Ferroptosis and Its Role in Diverse Brain Diseases.

Authors:  Abigail Weiland; Yamei Wang; Weihua Wu; Xi Lan; Xiaoning Han; Qian Li; Jian Wang
Journal:  Mol Neurobiol       Date:  2018-11-08       Impact factor: 5.590

6.  Transcriptomics of maternal and fetal membranes can discriminate between gestational-age matched preterm neonates with and without cognitive impairment diagnosed at 18-24 months.

Authors:  Athina Pappas; Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Josef C Cortez; Gaurav Bhatti; Nardhy Gomez-Lopez; Sonia S Hassan; Seetha Shankaran; Adi L Tarca
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

7.  Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease.

Authors:  Loubna Boukhzar; Abdallah Hamieh; Dorthe Cartier; Yannick Tanguy; Ifat Alsharif; Matthieu Castex; Arnaud Arabo; Sana El Hajji; Jean-Jacques Bonnet; Mohammed Errami; Anthony Falluel-Morel; Abdeslam Chagraoui; Isabelle Lihrmann; Youssef Anouar
Journal:  Antioxid Redox Signal       Date:  2016-03-16       Impact factor: 8.401

Review 8.  Selenium in the Therapy of Neurological Diseases. Where is it Going?

Authors:  Agnieszka Dominiak; Anna Wilkaniec; Piotr Wroczyński; Agata Adamczyk
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 9.  The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress.

Authors:  Hugo Juárez Olguín; David Calderón Guzmán; Ernestina Hernández García; Gerardo Barragán Mejía
Journal:  Oxid Med Cell Longev       Date:  2015-12-06       Impact factor: 6.543

10.  Selenotranscriptomic Analyses Identify Signature Selenoproteins in Brain Regions in a Mouse Model of Parkinson's Disease.

Authors:  Xiong Zhang; Yang-Lie Ye; Hui Zhu; Sheng-Nan Sun; Jing Zheng; Hui-Hui Fan; Hong-Mei Wu; Song-Fang Chen; Wen-Hsing Cheng; Jian-Hong Zhu
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.